Peptide Comparison
CagriSema vs Survodutide
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
CagriSema and Survodutide share the glp-1 class and carry roughly equivalent evidence (Phase 3 / Phase 3). On the catalogued data layer Survodutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Survodutide's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| CagriSema | Survodutide | |
|---|---|---|
| Class | Amylin + GLP-1 combination | GLP-1/glucagon dual agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | Dual amylin + GLP-1 receptor agonism | Dual GLP-1/glucagon receptor activation |
| Route | SC injection | SC injection |
| Half-life | ~7 days | Long-acting weekly |
| Dosage (research) | 2.4 mg / 2.4 mg SC weekly | 0.6-4.8 mg SC weekly |
| Evidence tier | Phase 3 | Phase 3 |
| Research depth | 113 indexed | 126 indexed |
| Availability | Investigational | Investigational |
| Reported risks | GI effects; Phase 3 REDEFINE mixed results | GI side effects; injection reactions |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick CagriSema or Survodutide?
CagriSema and Survodutide share the glp-1 class and carry roughly equivalent evidence (Phase 3 / Phase 3). On the catalogued data layer Survodutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Survodutide's evidence base is currently denser.
What is the difference between CagriSema and Survodutide?
CagriSema is classed as Amylin + GLP-1 combination; Survodutide is classed as GLP-1/glucagon dual agonist. Reported mechanism: CagriSema, Dual amylin + GLP-1 receptor agonism; Survodutide, Dual GLP-1/glucagon receptor activation. Reported half-life: CagriSema, ~7 days; Survodutide, Long-acting weekly. Routes in published studies: CagriSema, SC injection; Survodutide, SC injection.
Which has stronger evidence, CagriSema or Survodutide?
CagriSema and Survodutide sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CagriSema is graded Phase 3, with 25 cited sources on its reference page and 113 indexed studies. Survodutide is graded Phase 3, with 33 cited sources on its reference page and 126 indexed studies.
Which is more accessible, CagriSema or Survodutide?
Neither CagriSema nor Survodutide is an FDA-approved drug. Catalog status: CagriSema, Investigational; Survodutide, Investigational.
Are CagriSema and Survodutide ever combined?
CagriSema and Survodutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…